Passamonti Francesco, Rumi Elisa, Caramella Marianna, Elena Chiara, Arcaini Luca, Boveri Emanuela, Del Curto Cecilia, Pietra Daniela, Vanelli Laura, Bernasconi Paolo, Pascutto Cristiana, Cazzola Mario, Morra Enrica, Lazzarino Mario
Department of Hematology, Fondazione Istituto di ricovero e cura a carattere scientifico Policlinico San Matteo, University of Pavia, Italy.
Blood. 2008 Apr 1;111(7):3383-7. doi: 10.1182/blood-2007-11-121434. Epub 2008 Jan 10.
Post-polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV, we found that leukocytosis leukocyte count>(15x10(9)/L) at diagnosis is a risk factor for the evolution of post-PV MF. In a series of 68 patients who developed post-PV MF, median survival was 5.7 years. Hemoglobin level less than 100 g/L (10 g/dL) at diagnosis of post-PV MF was an independent risk factor for survival. The course of post-PV MF, however, is a dynamic process that implies a progressive worsening of clinical parameters. Using a multivariate Cox proportional hazard regression with time-dependent covariates, we found that a dynamic score based on hemoglobin level less than 100 g/L (10 g/dL), platelet count less than 100x10(9)/L, and leukocyte count more than 30x10(9)/L is useful to predict survival at any time from diagnosis of post-PV MF. The resulting hazard ratio of the score was 4.2 (95% CI: 2.4-7.7; P<.001), meaning a 4.2-fold worsening of survival for each risk factor acquired during follow up. In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF.
真性红细胞增多症后骨髓纤维化(真性红细胞增多症后骨髓纤维化)是真性红细胞增多症的晚期演变。在647例真性红细胞增多症患者中,我们发现诊断时白细胞增多(白细胞计数>(15×10⁹/L))是真性红细胞增多症后骨髓纤维化演变的危险因素。在一系列68例发生真性红细胞增多症后骨髓纤维化的患者中,中位生存期为5.7年。真性红细胞增多症后骨髓纤维化诊断时血红蛋白水平低于100 g/L(10 g/dL)是生存的独立危险因素。然而,真性红细胞增多症后骨髓纤维化的病程是一个动态过程,意味着临床参数会逐渐恶化。使用带有时间依赖性协变量的多变量Cox比例风险回归分析,我们发现基于血红蛋白水平低于100 g/L(10 g/dL)、血小板计数低于100×10⁹/L和白细胞计数高于30×10⁹/L的动态评分有助于预测真性红细胞增多症后骨髓纤维化诊断后任何时间的生存率。该评分得出的风险比为4.2(95%置信区间:2.4 - 7.7;P <.001),这意味着随访期间每获得一个危险因素,生存恶化4.2倍。总之,真性红细胞增多症诊断时的白细胞增多是真性红细胞增多症后骨髓纤维化演变的危险因素。基于血红蛋白水平、血小板和白细胞计数的动态评分可预测真性红细胞增多症后骨髓纤维化诊断后任何时间的生存率。